Establish a National Registry of REM Sleep Behavior Disorder

Chinese University of Hong Kong3,000 enrolled

Overview

In this proposed study, the investigators aim to build up a large cohort of Rapid eye movement sleep behavior disorder (RBD) to study the etiology and risk factors of neurodegeneration.

REM sleep behavior disorder (RBD) is a parasomnia characterized by abnormal behavioral manifestations during REM sleep. Accumulating evidence suggests that RBD is implicated as an integral part of disease progress of α-synucleinopathy neurodegeneration, such as Parkinson's disease (PD) and dementia with Lewy bodies.Previous studies have identified a series of neurocognitive, autonomic, clinical and neurobiological markers for neurodegeneration in iRBD, such as olfactory dysfunction, color vision deficit, autonomic dysfunction, tonic EMG activity during REM sleep, and psychiatric disorder. However, the prevalence rate of RBD was relatively low and most of the RBD studies only have 100 or below cases. and there might be ethic differences in RBD which indicates that the findings from western countries might not be applicable to Chinese. In these regards, the investigators aimed to build up a large cohort of Rapid eye movement sleep behavior disorder (RBD) to study the etiology and risk factors of neurodegeneration.

Study Type

OBSERVATIONAL

Enrollment

3,000

Conditions

REM Sleep Behavior Disorder

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Case: According to the ICSD-3 for the diagnosis of RBD 1. Sleep talking or complex movement during sleep; 2. Such movement was recorded by video PSG (AV-PSG) during REM sleep or according to history the movements were occurred during REM; 3. REM sleep without atonia (RWA) during PSG monitoring; 4. This abnormal phenomenon cannot be explained by other sleep disorder, psychiatric disease, drug or substance abuse. Control: Age and gender matched with consent 1. No RBD symptoms and PSG characteristics; 2. No neurological symptoms or diseases, MRI scan will be employed to exclude brain pathology; 3. No narcolepsy or hypersomnia, ruled out by multiple sleep latency test; 4. No history of mental illnesses or use of antidepressants. Exclusion Criteria: 1\. Subjects who refused to join the cohort.

Locations (1)

Department of psychiatry, Faculty of Medicine, The Chinese University of Hong Kong

Hong Kong, Hong Kong

RECRUITING

Outcomes

Primary Outcomes

Risk factors for neurodegenerative diseases in rapid eye movement sleep behavior disorder.

Risk factors for neurodegenerative diseases were investigated in rapid eye movement sleep behavior disorder by questionnaires, including general information, life history, occupational history and family history.

Time frame: 1 hour

Changes of neurocognitive biomarkers for neurodegenerative diseases in rapid eye movement sleep behavior disorder.

Based on the large cohort of RBD, the investigators aim to study the etiology and the progression of neurocognitive biomarkers for neurodegenerative diseases in rapid eye movement sleep behavior disorder by clinical assessment, including MoCA, olfactory dysfunction, color vision deficit and so on.

Time frame: Baseline and biennial follow-up, up to 20 years

Changes of autonomic dysfunctions for neurodegenerative diseases in rapid eye movement sleep behavior disorder.

Autonomic dysfunctions are also biomarkers for neurodegenerative diseases, the investigators aim to observe the changes of autonomic dysfunctions, including constipation, orthostatic hypotension and so on.

Time frame: Baseline and biennial follow-up, up to 20 years

Changes of REM-related EMG activity (REMREEA) and motor activity in rapid eye movement sleep behavior disorder.

The percentage of REM-related EMG activity (REMREEA) is the most reliable and valid marker in differentiating patients with RBD from normal controls. Both REMREEA and significant motor activity were recorded by video-polysomnography in rapid eye movement sleep behavior disorder.

Time frame: Baseline and biennial follow-up, up to 20 years

Central Contacts

Jihui Zhang, PhD

CONTACT

(852) 39197647 jihui.zhang@cuhk.edu.hk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.